Emergent BioSolutions Inc (EBS) 2014 Q3 法說會逐字稿

Good day, ladies and gentlemen, and welcome to the third quarter 2014 Emergent BioSolutions Incorporated earnings conference call. My name is Denise, and I'll be the operator for today. At this time, all participants are in listen-only mode. Later we will conduct a question-and-answer session.

(Operator Instructions)

As a reminder, this conference is being recorded for replay purposes. I would now turn the conference over to the company. Please proceed.

Thank you, Denise. Good afternoon, everyone. My name is Robert Burrows, Vice President of Investor Relations for Emergent. Thank you for joining us today as we discuss our financial results for the third quarter and nine months of 2014. As is customary, our call today is open to all participants. In addition, the call will be recorded and is copyrighted by Emergent BioSolutions. Participating on the call with prepared comments will be Dan Abdun-Nabi, President and Chief Executive Officer, Adam Havey, Executive Vice President and President of our BioDefense Division, Barry Labinger, Executive Vice President and President of our Bioscience Division, and Bob Kramer, Executive Vice President and Chief Financial Officer. For the call today, Dan will discuss the state of our business, including high-level current period financial results and an overview of divisional operations. Adam will discuss in greater detail the current state of the BioDefense operations, Barry will discuss in greater detail the current state of Bioscience's operations and Bob will conclude with a detailed discussion of our financial performance and outlook. Following prepared comments, we will conduct a Q&A session.

Before we begin I'm compelled to remind everyone that during today's call, either in our prepared comments or in the Q&A session, management may make projections and other forward-looking statements related to our business, future events, our prospects for future performance. These forward-looking statements reflect Emergent's current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve substantial risks and uncertainties, actual results may differ materially from those projected in any forward-looking statements. You're encouraged to review Emergent's filings with the SEC on Forms 10-K, 10-Q and 8-K for more information on the risks and uncertainties as to how the actual results.

During our prepared comments before the Q&A session, we may also refer to certain non-GAAP financial measures that involve adjustments to GAAP figures in order to provide greater transparency regarding Emergent's operating performance. Please refer to the two tables, one for the third quarter and the other for the nine-month period found in today's press release regarding our use of non-GAAP or adjusted financial measures and a reconciliation between our non-GAAP adjusted financial measures and our GAAP financial measures. For the benefit of those who may be listening to replay of the webcast, this call is held and recorded on November 6, 2014. Since then Emergent may have made announcements related to topics discussed during today's call. So again, please reference our most recent press releases and SEC filings. Emergent BioSolutions assumes no obligation to update information today's press release or as presented on this call except as maybe required by applicable laws and regulations. Today's press release may be found on the Investors homepage of our website.

With that introduction, I would now like to turn the call over to Dan Abdun-Nabi, Emergent BioSolutions President and CEO. Dan?

Thank you, Bob. Good afternoon everyone and thank you for joining our call. Over the course of 2014, we have made significant progress on our priorities to grow our business, consistent with our growth plan. Our revenue and net income performance was strong with third quarter revenue of $138 million. This is above the guidance of between $110 million to $125 million that we provided during our earnings call in August. For the quarter, our GAAP net income was approximately $22 million and our non-GAAP adjusted net income was $25 million.

Historically, our fourth quarter is our strongest quarter both in terms of revenue generation and net income performance. We anticipate this trend will continue this year, based on expected financial contributions from our BioThrax business, additional product sales in both divisions, contract manufacturing operations and our contacts, grants and collaborations business.

As announced in today's press release, given our strong financial performance to-date and our anticipated progress for the remainder of the year, we are increasing our full-year 2014 revenue guidance to between $440 million to $460 million and GAAP net income guidance to between $35 million to $45 million. We're also increasing our adjusted net income guidance to between $50 million to $60 million.

Operationally, we continue to make progress on our priorities across both divisions. For our BioDefense division, our core business continues to be strong and we remain on plan for the expansion of BioThrax manufacturing in Building 55. Moreover with a broader portfolio of BioDefense Products, we are making steady progress on expanding sales including international markets with additional growth anticipated in the fourth quarter.

We have advanced our cost containment objectives through consolidation of sales and marketing operations and the realignment of sectors of our workforce to create additional operational efficiencies and better leverage our resources. Adam will provide greater insights into the division operations during his prepared remarks.

We're also seeing solid progress in our Biosciences Division. Cangene integration continues to progress well. And in that process, we have identified synergies that can streamline our business operations to reduce costs including R&D spend. To that end, we are closing and selling select R&D facilities, consolidating certain operations and discontinuing programs that are not consistent with our growth plans. Barry will discuss this in greater detail during his prepared remarks.

Of note, we recently completed a significant collaboration agreement with MorphoSys that provides for joint worldwide development and commercialization of ES414, our immunotherapeutic protein targeting prostate cancer. Under the terms of the agreement, which provides for payments of up to $183 million, we received $20 million in an upfront fee with future payments based on traditional product development milestones. This is an exciting collaboration of a product candidate developed on our ADAPTIR platform and serves as an example of how we can expand our product portfolio with potentially valuable candidates, while effectively controlling overall R&D spend.

With respect to M&A, we continue to make progress on targets that will leverage our core competencies and drive further progress towards achieving growth in our business. For our BioDefense business, we're focused on medical countermeasures that governments currently stockpile or have international demand or address CBRN detection and diagnostic opportunities, or carry with them contract and grant funding.

For our Biosciences business, we continue to seek revenue generating opportunities to enhance both top line and bottom line performance and that are aligned with our current clinical focus areas. Further, our Biosciences team is pursuing partnerships for products developed on our ADAPTIR platform as well as for the platform itself.

In closing, I'd like to comment on our progress towards achieving our 2015 growth plan targets. As you might recall, in 2012, we set financial and operational targets to be achieved by the organization by the end of next year. Specifically, we targeted greater than $500 million in product and service revenue from at least three marketed products that would provide 2012 to 2015 net income CAGR of greater than 15%. At this point, we are on or ahead of schedule to achieve these goals. As we move towards 2015 we're planning the next phase of our corporate growth.

Currently, we are working with our Board of Directors to finalize our next multi-year strategic plan, which I expect to be able to share with you by the middle of next year. That concludes my prepared comments and then I'll turn it over to Adam Havey, who will discuss the BioDefense Division's operations in greater detail. Adam?

Thank you, Dan. During third quarter, we continued to make solid progress expanding our BioDefense business by focusing on what we do best, delivering CBRN countermeasures that address current health threats, advancing the development of additional medical countermeasures and platforms that address unmet public health needs, and building a flexible, vertically integrated manufacturing infrastructure capable of rapidly producing vaccines, therapeutics, small molecules, and other biologics, and expanding the use of our product portfolio on a global basis.

So let me highlight our recent accomplishments. In the third quarter, BioDefense revenues were just over $104 million, greatly contributing to the overall performance of the company year-to-date, as well as to the increased outlook for full year 2014. The third quarter revenue included $66 million in BioThrax sales and over $26 million in contract and grant revenue. BioThrax revenue was primarily from sales under our current five-year $1.25 billion contract with the CDC to deliver 44.75 million doses to the Strategic National Stockpile.

Delivery of BioThrax this quarter was on track and comparable to deliveries this time last year. Other BioDefense revenues totaled $21.4 million so far this year. RSDL sales for the three and nine-month periods were in line with our expectations, including first time purchase orders for a number of strategically important countries. As for BAT, we completed a substantial delivery of product to the SNS under our multiyear USG contract.

And lastly, AIG revenue was attributable to deliveries under our current USG contracts and we are working diligently to respond to FDA requests during the BLA review. We are optimistic that this product will be licensed in early 2015, which would trigger $7 million payment.

Next, let me update you on Building 55, our large scale BioThrax manufacturing facility. Back in September, we announced the initiation of the pivotal non-clinical study designed to show that BioThrax manufactured in Building 55 is comparable to that manufactured in our current approved facility. I'm pleased to report that this study is progressing according to plan and the in-life should be completed in Q1 2015.

We are targeting rolling sBLA submission to the FDA, the first part of which is planned to be submitted in early 2015. The key steps that need to be completed in order for this facility to be licensed include successful completion of an FDA inspection of the facility, completion of the non-clinical study and analysis of the data from that study and of course FDA approval of the entire package including data from the completed compatibility protocols. While there is much to do, our target continues to be completing all these activities in 2015. The schedule's tight, and it is possible that we will see the approval in early 2016.

On our contracts and grants side, we received two new contracts during the third quarter. First, the CDC exercised the contract option valued at $18.9 million for VIG, our therapeutic license for the treatment of complications due to smallpox vaccination. This three-year option supports ongoing stability of the product as well as collection of plasma. Second, in September we were awarded an NIAID contract valued at up to $29 million for the development of the dry formulation of NuThrax, our next generation anthrax vaccine that adds CPG 7909 Adjuvant to BioThrax. Dry formulations of NuThrax should enable storage at ambient and higher temperatures, thus eliminating the cold chain during shipping and storage. Switching gears to a topic that has been in the media recently.

I'd like to briefly touch on Emergent's efforts to respond to public health emergencies.

As you know, Ebola has been of tremendous concern mostly in West Africa but also here in the US. As our federal government works to respond to this crisis, they have issued task order requests for the production of developmental therapeutic candidates. In 2002, the government put infrastructure in place to quickly address emerging bio-threats when it created with industry Centers for Innovation in Advanced Development and Manufacturing. Our facility in Baltimore, Maryland, is one of those three designated centers. We will submit our proposal to BARDA next week and anticipate they may make one or more awards shortly thereafter.

At this point, we cannot predict the timing or the amount of any potential awards. We also anticipate that BARDA will likely issue additional task order requests related to Ebola in the coming months. Given our track record of partnering with the US government, we are prepared to assist the government in their response to this significant global health threat. That concludes my prepared comments. I'll now turn it over to Barry who will provide an update on the Biosciences Division.

Thank you, Adam. And good afternoon everyone. During the third quarter, we made good progress toward our goal of building a high growth biopharmaceutical business that meaningfully enhances patients' lives and is financially self-sufficient. Having completed a thoughtful portfolio assessment following the close of our Cangene acquisition, we've made some decisions and implemented them to restructure the business towards greater financial health. Let me focus on a few examples. We're very excited about our participation in the attractive immuno-oncology space, specifically our proprietary redirected T-cell cytotoxicity (RTCC) approach with our ADAPTIR platform. These are bi-specific therapeutic proteins that bind to antigens on tumor cells such as PSMA on prostate cancer cells, and to CD3, which is expressed on T-lymphocytes.

The anti-CD3 part of the molecule activates T cell-mediated immune response targeted against the tumor cells. Other companies are also pursuing RTCC as it is a very promising approach. Our technology offers them clear benefits. In pre-clinical studies, we see potent activation of T-cell activity with less release of cytokine. As you're probably aware, the release of cytokine at high levels can lead to safety issues. Our molecules also offer a pharmacokinetic advantages such long half-life leading to less frequent dosing, as well as manufacturability advantages.

Our most advanced RTCC program is ES414 our anti-PSMA, anti-CD3 molecule, which is poised to start Phase I in the next couple of months in patients with prostate cancer. Consistent with our overall strategy of securing partnerships for early-stage programs, we're pleased to have signed a co-development and commercialization agreement with MorphoSys, a successful German-based biotechnology company known for its scientific excellence and which is building an exciting development stage pipeline largely in oncology. In the third quarter, we recognized a little over $15 million of revenue from the $20 million upfront payment. We'll also earn a milestone payment upon dosing of the first patient in the Phase I study which is planned for late this year and is included in the financial outlook we're putting forward today. We'll be working in close collaboration with MorphoSys throughout development of ES414.

When we take into account the upfront and milestone payments and MorphoSys's responsibility for 64% of the development costs, our net investment in the development of ES414 will be small for a number of years to come. Once licensed, Emergent will commercialize ES414 in the US and Canada, and MorphoSys will commercialize in the rest of the world. We look forward to clinical data for this program over the next couple of years and we're also working towards additional partnerships around other product candidates from our RTCC platform. One of the programs in the Cangene portfolio was a recombinant human growth hormone product. We decided to discontinue investment in this program and eliminated essentially all spending on it earlier in the year. We're also seeking to exit the smaller of our two Winnipeg manufacturing facilities, known as Henlow Bay. The successful sale of this facility will help reduce our overhead costs moving forward.

We previously reported, our intention to hold off on Phase III development of Otlertuzumab for CLL unless and until we secure a partnership. As a consequence, spending on Otlertuzumab has been dramatically reduced from approximately $27 million in 2013 to a 2014 expectation of less than $10 million and much less than that in 2015 based on limiting the program to generate data from a low cost triple combination study that could be valuable in our partnering efforts. We also announced during Q3 the closure of our Munich R&D site, which has been dedicated to the development of our proprietary viral vaccine vector technology known as MVA. While promising the product candidates emerging from this platform are quite early stage, and we've determined that it's not consistent with our strategy to maintain investment in these programs.

The site will be substantially closed by the end of this year with modest shutdown activities extending into the first half of 2015. As these examples illustrate, we continue to build financial strength for our Biosciences business. We are working towards financial self-sufficiency for this business, while simultaneously assembling a portfolio of assets that will drive sustained revenue growth. We have an active business development effort targeting both partnerships for our existing products and technologies as well as acquisitions of new products that will provide near-term revenue growth.

With that, I'll turn the call over to Bob Kramer. Bob?

Thank you, Barry. And good afternoon to everyone on the call. We wanted to discuss our financial performance for the third quarter and then turn to the summary of where we are on a year-to-date basis as we head into the fourth quarter, targeting to deliver the increased revenue and income performance mentioned earlier on the call. Before I jump into the details of the third quarter, I'd like to highlight a few comments made on our Q2 earnings call in August as a backdrop to our Q3 results.

On that call, we discussed our expectation of increasingly strong financial performance in the second half of 2014 in order to meet our projections. We forecasted our Q3 revenues to be between $110 million and $125 million, which reflected this improved performance. We also guided that our sales mix would generate improved operating margins in the second half of the year as higher margin BioThrax sales became a greater percentage of our overall product revenue. And lastly we discussed our continued focus on advancing our ADAPTIR platform product candidates through partnerships as a way of demonstrating the value of our technology and importantly deferring R&D costs.

During the third quarter, we made significant progress on all fronts, starting with total revenue, which was around $138 million, outperforming the midpoint of our range by $20 million and bettering our Q2 total by 25%. This performance was a result of a combination of the continued strength of our BioDefense business and boosted by the Bioscience business and the recognition of approximately $15 million of $20 million upfront fee associated with the partnership with MorphoSys focused on ES414, our ADAPTIR-based prostate cancer product candidate.

Drilling down a bit, total product sales for the quarter came in at $85 million. Of that, $77 million was generated from our BioDefense Division led by BioThrax in its $66 million contribution in the quarter. The other BioDefense products contributed $11 million in sales for the quarter. Bioscience products contributed an additional $7 million of revenue, all of which was incremental to last year due to the timing of the Cangene acquisition earlier this year. In addition to the $85 million product revenue, we generated contracts, grants and collaboration revenue of $44 million along with CMO revenue of $9 million.

The contracts, grants and collaboration revenue reflects the impact of the recognition of the MorphoSys upfront payment. As a result of the improved sales mix, our consolidated gross margin for the quarter was 65%, up from the prior quarter of 61%. As mentioned on the last call, the new norm for our consolidated gross margin is between 60% and 70%. So with our Q3 results, we are right in the middle of this new range.

Walking further down the income statement, gross R&D expense for the quarter was $44 million or $15 million above last year's quarter primarily due to the development programs acquired from Cangene. Adjusting for the contracts, grants and collaboration revenue line, which reflects reimbursement for development costs, our net R&D spend for the quarter was de minimis at approximately $100,000. SG&A expense for the quarter was $30 million, $8 million above prior year quarter. Again, largely due to the additional costs associated with the Cangene acquisition.

Importantly, however, our SG&A for each of the three quarters of 2014 has remained relatively constant levels at around $30 million. We will continue to pursue further optimization of this line item as we grow the business.

The favorable revenue and margin performance during the quarter were key contributors to generating $22 million in GAAP net income or $0.58 per basic share. This compares to the prior year GAAP net income of $13 million or $0.37 per share. On a non-GAAP basis, adjusted net income was $25 million or $0.67 per share compared with $16 million or $0.43 per share for the comparable period in 2013.

Turning to the year-to-date performance, the nine-month financials reflect the continued fundamental strength of the BioDefense business aided by the Company's efforts to manage net R&D costs and our continued focus on sharing development risk by securing opportunities to partner with third parties on R&D projects, particularly for our ADAPTIR platform candidates.

For the nine-month period of 2014, our GAAP net income of $7 million includes $13 million of adjustments for acquisition-related costs and other non-recurring and non-cash expenses. After adjustments, year-to-date adjusted net income was $20 million. Although this is essentially even for the adjusted net income for the same period in 2013, it does represent accelerated net income performance as compared to the prior period. In addition to this strengthening financial performance reflected in our income statement, our balance sheet continues to improve.

At quarter end, our cash position was $242 million with another $44 million of receivables. As a result of the financial performance in Q3, we put ourselves in a good position to deliver increasingly strong financial results in Q4. Accordingly, we've increased our outlook for 2014 across all three metrics. Specifically, we've increased our revenue guidance to between $440 million and $460 million. We've increased our GAAP net income guidance to between $35 million and $45 million and we've increased our adjusted net income guidance to between $50 million and $60 million.

That concludes my prepared remarks and I'll now turn the call over to the operator who will begin the question-answer session.

(Operator Instructions) Jim Molloy, Summer Street.

Hey guys, thanks for taking my question. I had a question on maintenance thing, what were the actual RSDL sales in the quarter and then a follow-up on that, on a bigger picture. I know Adam touched on the Ebola RFP you guys submitted. This $6 billion number that we're hearing in the papers that the President is looking throw at this disease, how much of that realistically is, to put it bluntly up for grabs for you guys, for Glaxo and for Novartis, potential manufacturing.

Okay. Thanks, Jim, appreciate you participating on the call. On the RSDL, first let me answer the second question and I will turn over RSDL to the team. So it's true there is $6 billion the total request that's been sent over. About $155 million, $160 million has been allocated to BARDA, specifically for the development of medical countermeasures, therapeutics and vaccines. So, currently that might, depending on what the Congress does with it, that might be a level of additional funding that will be provided to BARDA, over and above what they currently have allocated for the Ebola crisis. So hopefully that gives you some clarity. So on the RSDL front, Adam, I think the question was what were the RSDL sales?

As you can tell, Jim, as our portfolio has grown and expanded, we're going to focus on BioThrax sales as the primary driver and kind of capturing all of our other product sales really in other biodefense. We're not going to go to that level of granularity as we move forward. So, that's something we'll have to estimate it on a gross level with the additional products in our portfolio.

Yes, and a little bit more clarity on that as well. Jim, as specific products start to gain additional market share, and become larger and larger in terms of their revenue generation, we will give greater visibility as they become bigger in percentage for the total revenue overall.

Okay, fair enough. A couple quick follow-up questions, and if I could, thank you for that. R&D really fell off the table I guess in a good way to have a low number there. Is that sustainable? Where does that number get to on the actual spend, but you guys know that obviously most of the R&D, is the contract grants reimbursed R&D? And then talk a bit about the fully diluted shares kind of took a jump in the quarter. What was the driver of that and will you stay at these levels?

Jim, this is Bob. So on the R&D for the quarter, the net R&D reflects clearly the netting of the $15 million MorphoSys upfront payment. So you shouldn't expect us to have essentially zero net R&D on a quarterly basis going forward but as we've talked about on prior calls, our emphasis is on continuing to manage R&D costs look for opportunities to partner certain technologies like the ES414 candidate and gradually walk that net R&D number as a percent of our revenue, down from historical levels of 20% to 25% down to a high teens number. So we'll continue to make progress there.

I'll just add comment to that, Bob. Jim as you know it's been a priority for us to partner these assets and initially, we've been spending quite a bit in time on the Otlertuzumab partnering and it turned out that ES414 was the first to get across the goal line. So this remains a focus for us across the portfolio. And actually for the platform itself, we think that the ADAPTIR platform being bi-specific is state-of-the-art, it's a very interesting platform. So to Bob's point, you can't expect to see this on a regular basis, but it is a part of the way in which we intend to operate our business.

So don't be surprised in the future when we announce deals that are around partnering particular assets or the platform as a whole.

And Jim, on the question about the fully diluted or the weighted average number of shares in the quarter we're reflecting the impact of the convert shares. We did not include them last time because we had a net loss cumulative as of the end of six months. So it was inappropriate for us to reflect those fully diluted weighted shares.

Excellent. And I guess last question. Should we be expecting a another acquisition to get to the $500 million at some point here in 2015?

It's a great question. So the short answer is yes, we are looking at acquiring. And it's really not so much around whether we get to the $500 million but that's just the way in which we intend to build both businesses. And where we are right now, there are a number of interesting targets that we've identified for both Biosciences and BioDefense and some of them could be meaningful contributors to top line and bottom line. So I'm actually quite excited about the prospects for completing transactions, but as you know, it's a timely process and we need to be patient and we need to be prudent and as we discussed in the past with you, we have specific metrics and criteria. We don't get wedded to an opportunity if it turns out, if it's part of an auction and we get out bid, we're out bid. And if we can't do it on the terms we feel appropriate for our shareholders, we will walk, which has happened in the past. So we remain active but prudent in terms of our approach to M&A.

Marc Frahm, Cowen and Company.

Hey, thanks for taking my question. Just kind of on the housekeeping of Building 55 as we move towards approval. Do you guys expect to kind of press release when these major steps are finished or just are we going to have to wait until that application is complete?

Yeah, so thanks, Marc, for joining the call. (inaudible) In terms of our communication of Building 55, we do intend to keep people apprised of developments as we go forward.(inaudible).

And then also again as we all are anticipating and eventually being approved, when can we expect to see some movement on kind of negotiating the next contract for BioThrax and will that necessarily include the Building 55 or might it happen sooner and may not reflect that excess capacity?

Yeah, it's a great question and I think historically (technical difficulty) Our expectation and experience with the CDC has been at least in this context, we would expect to start discussions with them once the application starts to go in. I think they would look at this and say there's no need to have a discussion until we know you're actually across the goal line with getting the application at least started, and then there's some lead-time associated with any of these contract negotiations. So that's an area where we likely will not provide great visibility to investors, those discussions are confidential, but we do anticipate making progress during the course of next year, potentially starting those discussions as early as the second quarter next year.

Okay, and then there's been some hope that you could start selling more to non-US governments will all this kind of have to wait until we have a new US contract or can you can do that in parallel?

Yes. So, Mark, this is Adam Havey. We do that in parallel, obviously the upside in capacity at 55 really creates, I'd say, a little bit more opportunity internationally, but as we've mentioned in the past, we continue to work on expanding our reach internationally for BioThrax, for BAT, for AIG, for VIGIV and RSDL. So that's a major focus for us right now, and it'll continue to be a focus in 2015. We think we can build some demand in those markets prior to approval of Building 55 and we'll continue to see some movement there in 2015.

Okay. And then finally back to the Ebola task order, is funding of that going to be contingent on the funding requests from Obama getting filled by Congress or does BARDA have enough money sitting around right now to fill this request?

So that's a great question. BARDA does have funds. We don't have complete transparency in terms of exactly how much they have and how much they will be allocating to each of the activities they have underway. And as you can appreciate, this is a fairly expansive program that they're launching here. My suspicion and I think it's just common sense, they don't have adequate funding to do everything that they would like to do, but they do have funds in order to get these programs started and then they will continue to fill that pipeline through additional appropriations as they, materialize from Congress.

Randy Scherago, LaSalle Street Capital Management.

Hi guys, great quarter. Just a couple of quick questions, just some housekeeping. The facility in Winnipeg, is that going to be a gain write-off or sort of a net neutral to earnings going forward? Number two, any clarity on what you're doing with IXINITY? Are you shutting or rolling off of that program, are you going forward with it? Will there be cost associated with it? And the third was, was the shut down sort of a normal shut down for Building 12 in Lansing? Are you back up and running again and making BioThrax?

Alright, Randy. This is Bob, I'll take the first part and I think Barry will answer the second and probably Adam the third. So you get three of us in a row here. I think on the write-down or the sale of the facility in Winnipeg, there may be a small gain, but it won't have a material impact on our statements overall.

Okay. The question about IXINITY, as you know, we received a complete response letter from the FDA at the end of July when we reached our PDUFA date. We've since had discussions with the agency and reached resolution on the content of the response to that CRL, which we have submitted. So the program is back under review and if the review is completed successfully, then we do plan to launch this product in 2015. There is no additional cost associated with responding to the issues that were raised in the CRL. So we have some ongoing studies that we've had in place anyway and will continue into post marketing commitments and we've had some preparation for the launch on the commercial side, but all consistent with the plan. We just had a bit of a delay in getting to the approval on the launch.

Would the launch be late 2015?

More around the middle of 2015.

And Building 12. So as you mentioned, we were in shut down and we've successfully come out of shut down, actually we came out a few days early and things look great for Building 12 moving forward.

We have no further questions. I would now turn the call over to Mr. Bob Burrows for any closing remarks. Please proceed.

Thank you, Denise. With that ladies and gentlemen, we now conclude the call. Thank you for your participation. Please note that today's call has been recorded and a replay will be available beginning later today. Alternatively, there is available a webcast of today's call, an archived version of which will be available later today accessible through the company website. Thank you again and we look forward to speaking to all of you in the future. Goodbye.

This concludes today's conference. You may now disconnect. Have a great day, everyone.